The -463G/A polymorphism in myeloperoxidase gene and cervical cancer.
Alexander Musteaa b, Georg Heinze, Jalid Sehouli, Dominique Koensgen, Andrea Wolf, Guţu Lilian, Sofroni Dumitru, Cristina Pirvulescu, Elena Ioana Braicu, Eva Schuster, Robert Zeillinger, Dan Cacsire Castillo‐Tong
- aDepartment of Gynaecology and Obstetrics, Charité, Campus Virchow-Klinikum, Medical University of Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. alexander.mustea@charite.de
- bDepartment of Gynaecology and Obstetrics, Charité, Campus Virchow-Klinikum, Medical University of Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
BACKGROUND: Cervical cancer is the leading cause of cancer-related death in women in developing countries. The -463 type G polymorphism of the MPO gene has been correlated with higher MPO expression and increased risk of various types of cancers. Our study was performed in order to evaluate the association between the -463G polymorphism and the prevalence of cervical cancer. MATERIALS AND METHODS: In our prospective study, 149 patients with cervical cancer and 126 patients without any malignancies were enrolled. RESULTS: No significant difference was found between genotype distributions in the cervical cancer patients and the control group. There was also no significant association of the genotype distributions with clinical prognostic factors. However, significantly lower A allele frequency of the -463 polymorphism of the MPO gene was found in our study group in comparison with that of the average Caucasian population. CONCLUSION: The -463 polymorphism of the MPO gene was not associated with susceptibility to cervical cancer.
TL;DRThe -463 polymorphism of the MPO gene was not associated with susceptibility to cervical cancer and there was also no significant association of the genotype distributions with clinical prognostic factors. (Semantic Scholar)